Local Management of Oligometastases in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Riudavets Melia, M. [1 ]
Del Carpio Huerta, L. [1 ]
Barba Joaquin, A. [1 ]
Anguera Palacios, G. [1 ]
Sullivan, I. [1 ]
Callejo Perez, A. [1 ]
Farre, N. [2 ]
Torrego, A. [3 ]
Pajares, V. [3 ]
Martinez, E. [4 ]
Trujillo, J. C. [4 ]
De Quinana, C. [5 ]
Majem Tarruella, M. [1 ]
机构：
[1] Hosp La Santa Creu & St Pau, Med Oncol, Barcelona, Spain
[2] Hosp La Santa Creu & St Pau, Radiat Oncol, Barcelona, Spain
[3] Hosp La Santa Creu & St Pau, Pneumol, Barcelona, Spain
[4] Hosp La Santa Creu & St Pau, Orac Surg, Barcelona, Spain
[5] Hosp La Santa Creu & St Pau, Neurosurg, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Non-Small Cell Lung Cancer; Oligometastases; Management;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-072
引用
收藏
页码：S2095 / S2095
页数：1
相关论文
共 50 条
  • [31] Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study
    Migliorino, Maria Rita
    Santo, Antonio
    Romano, Giampiero
    Cortinovis, Diego
    Galetta, Domenico
    Alabiso, Oscar
    Carteni, Giacomo
    Vari, Sabrina
    Fasola, Gianpiero
    Pazzola, Antonio
    Giuffrida, Dario
    Zaniboni, Alberto
    Caprioli, Alberto
    Longo, Flavia
    Acciai, Valentina
    de Marinis, Filippo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (05) : 783 - 791
  • [32] Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)
    Mascaux, Celine
    Ekman, Simon
    Dooms, Christophe
    Shepherd, Frances A.
    CURRENT PULMONOLOGY REPORTS, 2013, 2 (01) : 1 - 9
  • [33] Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales
    Crook, A
    Duffy, A
    Girling, DJ
    Souhami, RL
    Parmar, MKB
    EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (07) : 1552 - 1558
  • [34] An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update
    Cerbone, Luigi
    Benitez, Jose Carlos
    Planchard, David
    Genova, Carlo
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (07) : 809 - 819
  • [35] Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)
    Schmid-Bindert, Gerald
    TARGETED ONCOLOGY, 2013, 8 (01) : 15 - 26
  • [36] Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC)
    Shicheng Guo
    Fengyang Yan
    Jibin Xu
    Yang Bao
    Ji Zhu
    Xiaotian Wang
    Junjie Wu
    Yi Li
    Weilin Pu
    Yan Liu
    Zhengwen Jiang
    Yanyun Ma
    Xiaofeng Chen
    Momiao Xiong
    Li Jin
    Jiucun Wang
    Clinical Epigenetics, 2015, 7
  • [37] Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)
    Fumihiro Tanaka
    Kazue Yoneda
    Surgery Today, 2016, 46 : 25 - 37
  • [38] Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)
    Bodor, J. Nicholas
    Boumber, Yanis
    Borghaei, Hossein
    CANCER, 2020, 126 (02) : 260 - 270
  • [39] Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)
    Tanaka, Fumihiro
    Yoneda, Kazue
    SURGERY TODAY, 2016, 46 (01) : 25 - 37
  • [40] Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Papachristos, A.
    Masinde, S.
    Davis, J. D.
    Gullo, G.
    Rietschel, P.
    Paccaly, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S308 - S309
12345